Immunomedics (IMMU) Misses Q4 EPS by 46c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Immunomedics Announces Fourth Quarter and Fiscal Year 2018 Results and Provides Corporate Update
August 23, 2018 4:00 PM EDTBiologics License Application (BLA) Accepted for Filing and Granted Priority Review by the U.S. Food and Drug Administration (FDA)
U.S. Commercial Launch Preparations on Track
Lifecycle Management Strategy Implemented to Advance Sacituzumab Govitecan to Earlier Lines of Therapies and Broaden into Other Solid Cancer Indications
MORRIS PLAINS, N.J., Aug. 23, 2018 (GLOBE NEWSWIRE) -- Â Immunomedics,... More
